



Supplementary Fig. 1. Study scheme. Patients with type 2 diabetes mellitus who fail to achieve target glycosylated hemoglobin on metformin monotherapy were randomized to alogliptin (Alo) mono add-on, pioglitazone (Pio) mono add-on, or Alo+Pio double add-on.